SARS-CoV-2 infection in high-risk children following tixagevimab-cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study.
cancer
coronavirus
hematopoietic cell transplant
immunocompromised
monoclonal antibodies
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
05
2023
accepted:
10
07
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
From 8 December 2021 to 26 January 2023, tixagevimab-cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28-135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.
Identifiants
pubmed: 37601666
doi: 10.3389/fonc.2023.1229655
pmc: PMC10436088
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1229655Informations de copyright
Copyright © 2023 Hijano, Ferrolino, Swift, Michaels, Max, Hayden, Wolf, Dallas, Greene, Richardson, Hakim, Morton and Cross.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Infect Dis. 2023 Mar 21;76(6):1067-1073
pubmed: 36310534
J Korean Med Sci. 2022 Feb 07;37(5):e35
pubmed: 35132841
Clin Infect Dis. 2023 Jan 6;76(1):165-171
pubmed: 35245942
Elife. 2023 Mar 28;12:
pubmed: 36975207
J Med Virol. 2022 Oct;94(10):4860-4868
pubmed: 35750492
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Pediatrics. 2020 Oct;146(4):
pubmed: 32665373
Lancet Infect Dis. 2023 May;23(5):528-530
pubmed: 37030318
Pediatr Blood Cancer. 2021 Jun;68(6):e28915
pubmed: 33538100
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):530-534
pubmed: 32652521
Front Public Health. 2023 Mar 23;11:1108546
pubmed: 37033069
Infection. 2023 Mar 16;:
pubmed: 36929650
Clin Exp Rheumatol. 2023 May;41(5):1202-1203
pubmed: 36826787
Postgrad Med J. 2020 Dec;96(1142):753-758
pubmed: 32563999
J Clin Immunol. 2023 Jul;43(5):865-868
pubmed: 36862321
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833
pubmed: 35737591
Transl Behav Med. 2021 Dec 14;11(12):2194-2199
pubmed: 34529080
Lancet Child Adolesc Health. 2021 May;5(5):e12-e13
pubmed: 33713603
Drugs Today (Barc). 2022 Nov;58(11):539-546
pubmed: 36422515
JAMA. 2023 Jun 27;329(24):2118
pubmed: 37285173
Sci Rep. 2022 Apr 26;12(1):5966
pubmed: 35474313
Bone Marrow Transplant. 2023 Mar;58(3):340-342
pubmed: 36481838
Br J Haematol. 2023 Jun;201(5):813-823
pubmed: 37006158
PLoS One. 2023 Apr 27;18(4):e0275356
pubmed: 37104498
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
J Hematol Oncol. 2023 Apr 1;16(1):32
pubmed: 37005697
J Med Virol. 2022 Jun;94(6):2402-2413
pubmed: 35099819
J Allergy Clin Immunol Glob. 2023 May;2(2):100081
pubmed: 36777105
Postgrad Med J. 2022 Oct 1;98(1164):756-764
pubmed: 37062994
Clin Transplant. 2023 Apr;37(4):e14913
pubmed: 36651598
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
Front Public Health. 2023 Jun 30;11:1163360
pubmed: 37457286
Blood Cancer J. 2022 Dec 23;12(12):173
pubmed: 36550105
Lancet Oncol. 2021 Oct;22(10):1416-1426
pubmed: 34454651
Ann Hematol. 2023 Apr;102(4):819-827
pubmed: 36862167